FIP antiviral success brings a new stewardship challenge: full analysis

A hard-won breakthrough in feline medicine is entering its next phase: stewardship. In a March 2025 Worms & Germs analysis, University of Guelph infectious disease expert Scott Weese warns that the profession could jeopardize “game-changing” FIP antivirals if GS-441524 and related drugs are used indiscriminately, particularly outside well-supported FIP cases. His core argument is that resistance risk is relatively low when treating cats with FIP itself, but potentially much higher if antivirals are used against enteric feline coronavirus circulating in multi-cat environments. (wormsandgermsblog.com)

That warning comes after a rapid shift in access and practice. On May 10, 2024, FDA said it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for an individual cat with FIP under the conditions in Guidance for Industry #256, while also stressing that these compounded products are still unapproved and not technically “legal.” In parallel, treatment guidance has become more nuanced, including greater use of oral GS-441524, more individualized dosing, and less routine reliance on injectable induction except in critically ill cats or those with absorption concerns. (fda.gov)

Weese’s resistance argument hinges on transmission dynamics. He notes that FIP virus itself is generally not considered meaningfully transmissible cat-to-cat, so a resistant variant that emerges during treatment of an individual FIP case would likely end with that patient. The larger concern is selection pressure in intestinal feline coronavirus, which is common and readily spread in feces. If resistant enteric strains emerge and circulate, those viruses could later seed FIP cases that no longer respond to frontline therapy. That is why he draws a sharp line between treating confirmed or strongly suspected FIP, where benefit is high, and using GS-441524 more broadly for enteric coronavirus, where clinical benefit appears limited and population-level resistance risk could be much greater. (wormsandgermsblog.com)

The broader evidence base helps explain why this matters so much. Published studies have shown strong outcomes with antiviral treatment for FIP, including prospective data for remdesivir with or without transition to oral GS-441524, a blinded non-inferiority study finding oral remdesivir and GS-441524 both effective for effusive FIP, and newer reports suggesting molnupiravir can be effective as first-line, maintenance, or rescue therapy in selected cats. A large 2026 retrospective study of 629 cats treated with GS-441524 also reinforces how dramatically prognosis has changed, even as outcomes still vary by presentation and timing. (pubmed.ncbi.nlm.nih.gov)

There are also signs the field is maturing from access debates to optimization and surveillance. Cornell researchers have launched work specifically aimed at detecting whether antiviral resistance sequence markers have emerged in U.S. feline coronavirus strains after widespread antiviral use, including in cats that relapsed or died despite treatment. Cornell’s Fight FIP team has also publicly emphasized the risk of resistance with unregulated antiviral use and pointed to combination therapy as a possible future strategy, though that remains an area for further research rather than standard practice. (vet.cornell.edu)

Why it matters: For veterinary professionals, this is a reminder that stewardship applies to antivirals, too. As access improves and pet parents increasingly arrive informed about GS-441524, remdesivir, and molnupiravir, the pressure to treat empirically or to stretch these drugs into poorly supported indications may grow. The risk is that success against FIP could create the conditions for resistance if clinics, shelters, catteries, or tele-adjacent prescribing pathways normalize antiviral use for common enteric feline coronavirus or for weakly substantiated diagnoses. Protecting efficacy will likely mean better diagnostic discipline, careful dose selection, follow-up monitoring, and clear communication with pet parents about when treatment is warranted, and when it is not. (wormsandgermsblog.com)

What to watch: The next key developments are likely to be resistance surveillance data, more refined dosing and monitoring protocols, and any further regulatory movement around compounded FIP antivirals or alternative agents such as molnupiravir. If resistance markers begin to appear, expect stewardship guidance to become much more explicit, especially for shelters, rescue settings, and multi-cat households. (fda.gov)